TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04400968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular therapy
Description: The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen \[FT2\], uterus \[FT5\], sympathetic \[HI4\], kidney \[CS6\], heart \[CI4\], endocrine \[IT2\] and thalamus \[PC2\].

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Auricular therapy Placebo group
Description: Sham auricular therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: kinesio tape Placebo group
Description: Sham kinesio tape
Study: NCT03931993

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL
Study: NCT03155854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pretendinous cord excision
Description: The cord/palmar fascia will be excised during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Division/manipulation of the cord
Description: The pretendinous cord will be divided and incised during surgery.
Study: NCT03622255

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MINST
Description: Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINST with EMD
Description: Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
Study: NCT03282136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretin Effect
Description: The patients will receive incretins therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac Resynchronization therapy defibrillator device
Description: The patients will receive a Cardiac Resynchronization therapy defibrillator device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization therapy defibrillator device
Description: The patients will receive a Cardiac Resynchronization therapy defibrillator device
Study: NCT04515056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 10 µg
Description: The area will be exposed to 10 µg of papain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 50 µg
Description: The area will be exposed to 50 µg of papain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 100 µg
Description: The area will be exposed to 100 µg of papain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: The area will be exposed to vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 1 SPT
Description: Papain will be applied by 1 SPT prick thought the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 5 SPT
Description: Papain will be applied by 5 SPT pricks thought the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papain 25 SPT
Description: Papain will be applied by 25 SPT pricks thought the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
Study: NCT02367430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention With Buried in Treasures included
Description: Critical Time Intervention and BIT Workshop
Study: NCT01928667

Intervention type: OTHER
Intervention: Whole saliva sample
Description: Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
Study: NCT04448639

Intervention type: DIAGNOSTIC_TEST
Intervention: Bloodtest
Description: cardiac biomarkers
Study: NCT03704506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reyanning mixture
Description: Reyanning mixture , 20ml by mouth , 3 times per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reyanning mixture
Description: Reyanning mixture , 20ml by mouth , 3 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxil capsule
Description: amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
Study: NCT04456647

Intervention type: OTHER
Intervention: Parenteral nutrition
Description: Parenteral nutrition treatment in palliative care
Study: NCT01041989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Description: Individual counseling sessions and group meetings will be organized.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Guided muscle strength training and aerobic exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of vascular risk factors
Description: Monitoring and maintenance of metabolic and vascular risk factors
Study: NCT01861977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Workshop
Description: Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
Study: NCT00913523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Tampon with GML
Description: Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control - Tampons without GML
Description: There is no intervention associated with these arms - they are sham controls.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control - Tampons without GML
Description: There is no intervention associated with these arms - they are sham controls.
Study: NCT02932553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVS+OMT
Description: bioresorbable vascular scaffold implantation plus optimal medical treatment
Study: NCT01457274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation depth
Description: The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation depth
Description: The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80).
Study: NCT01416935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Amiodarone
Description: This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
Study: NCT00307164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NucleomaxX
Description: 36 g sachet taken orally three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NucleomaxX placebo
Description: 36 g placebo sachet taken orally three times daily
Study: NCT00947232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
Study: NCT00583271

Intervention type: DRUG
Intervention: triamcinolone
Description: 80mg of triamcinolone injected into the celiac ganglion during the EUS-CB

Intervention type: DRUG
Intervention: 98% dehydrated alcohol
Description: 10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
Study: NCT03042364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pipelle de Cornier
Description: RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
Study: NCT02871583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lichtenstein
Description: tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kugel
Description: preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
Study: NCT01547598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost ophthalmic solution 0.004%
Description: Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
Study: NCT03704506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxil capsule
Description: amoxil capsule , 0.5g by mouth , 3 times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyanning mixture simulator
Description: Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
Study: NCT01547598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost ophthalmic solution 0.004%
Description: Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% / timolol 0.5% combination ophthalmic solution
Description: DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost ophthalmic solution 0.01%
Description: LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
Study: NCT01496365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565 tablet
Description: 5mg and 10mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin capsule
Description: 75mg and 150mg over-encapsulated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo capsule
Study: NCT00565266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide inhalation powder 18 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate
Description: salmeterol xinafoate inhalation powder 50 mcg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
Study: NCT00777634

Intervention type: OTHER
Intervention: No intervention.
Description: There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.

Intervention type: OTHER
Intervention: No intervention.
Description: There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
Study: NCT02480699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recurring blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary survey
Description: A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
Study: NCT02503098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record adaptive smartphone application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovery Record standard smartphone application
Study: NCT04719299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell-Play-Do
Description: Using smart phone application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tell-Show-Do
Description: Using traditional behavior management technique
Study: NCT05194670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced depth of focus IOL
Description: Acunex Vario AN6V, enhanced depth of focus IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monofocal IOL
Description: Acunex AN6, monofocal IOL
Study: NCT02924597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia robot-assisted laparoscopic RFA assisted TE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zero ischemia robot-assisted laparoscopic partial nephrectomy
Study: NCT03453723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magic glove hypnosis technique
Description: Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
Study: NCT04413370

Intervention type: DIAGNOSTIC_TEST
Intervention: Dry eye diagnostic test
Description: The artificial intelligent dry eye screening platform

Intervention type: DIAGNOSTIC_TEST
Intervention: Dry eye diagnostic test
Description: The artificial intelligent dry eye screening platform

Intervention type: DIAGNOSTIC_TEST
Intervention: Dry eye diagnostic test
Description: The artificial intelligent dry eye screening platform
Study: NCT02346929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guide
Description: Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
Study: NCT00878293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS Continus®
Description: 60 mg, capsule, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid formulation and capsule, once daily
Study: NCT04409522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The usual treatment
Description: Participants in this group will receive the usual treatment of COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The usual treatment
Description: Participants in this group will receive the usual treatment of COVID-19